Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jun 15;7(2):49.
doi: 10.3390/antibiotics7020049.

Future Prospects for Neisseria gonorrhoeae Treatment

Beatriz Suay-García  1 , María Teresa Pérez-Gracia  2
Affiliations
Review

Future Prospects for Neisseria gonorrhoeae Treatment

Beatriz Suay-García et al. Antibiotics (Basel). .

Abstract

Gonorrhea is a sexually transmitted disease with a high morbidity burden. Incidence of this disease is rising due to the increasing number of antibiotic-resistant strains. Neisseria gonorrhoeae has shown an extraordinary ability to develop resistance to all antimicrobials introduced for its treatment. In fact, it was recently classified as a “Priority 2” microorganism in the World Health Organization (WHO) Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery and Development of New Antibiotics. Seeing as there is no gonococcal vaccine, control of the disease relies entirely on prevention, diagnosis, and, especially, antibiotic treatment. Different health organizations worldwide have established treatment guidelines against gonorrhea, mostly consisting of dual therapy with a single oral or intramuscular dose. However, gonococci continue to develop resistances to all antibiotics introduced for treatment. In fact, the first strain of super-resistant N.gonorrhoeae was recently detected in the United Kingdom, which was resistant to ceftriaxone and azithromycin. The increase in the detection of resistant gonococci may lead to a situation where gonorrhea becomes untreatable. Seeing as drug resistance appears to be unstoppable, new treatment options are necessary in order to control the disease. Three approaches are currently being followed for the development of new therapies against drug-resistant gonococci: (1) novel combinations of already existing antibiotics; (2) development of new antibiotics; and (3) development of alternative therapies which might slow down the appearance of resistances. N. gonorrhoeae is a public health threat due to the increasing number of antibiotic-resistant strains. Current treatment guidelines are already being challenged by this superbug. This has led the scientific community to develop new antibiotics and alternative therapies in order to control this disease.

Keywords: Neisseria gonorrhoeae; antibiotic resistance; gonorrhea; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Timeline representing the introduction of treatments used against gonorrhea (right) and the first reports of resistance (left) [4,7,8].
See this image and copyright information in PMC

References

    1. World Health Organization (WHO) Global Action Plan to Control the Spread and Impact of Antimicrobial Resistance in Neisseria gonorrhoeae. WHO; Geneva, Switzerland: 2012. [(accessed on 15 May 2018)]. Available online: http://apps.who.int/iris/bitstream/10665/44863/1/9789241503501_eng.pdf.
    1. Bolan G.A., Sparling P.F., Wasserheit J.N. The emerging threat of untreatable gonococcal infection. N. Engl. J. Med. 2012;366:485–487. doi: 10.1056/NEJMp1112456. - DOI - PubMed
    1. Hook E.W., 3rd, Kirkcaldy R.D. A Brief History of Evolving Diagnostics and Therapy for Gonorrhea: Lessons Learned. Clin. Infect. Dis. 2018 doi: 10.1093/cid/ciy271. - DOI - PMC - PubMed
    1. Unemo M., Del Rio C., Shafer W.M. In: Emerging Infections 10. Scheld W.M., Hughes J.M., Whitley R.J., editors. American Society for Microbiology; Washington, DC, USA: 2016. Chapter 12.
    1. Centers for Disease Control and Prevention (CDC) Cephalosporin-Resistant Neisseria gonorrhoeae Public Health Response Plan. CDC; Atlanta, GA, USA: 2012. pp. 1–43.